



Genetics and Treatment of Dilated Cardiomyopathy

Guest Editor:

Prof. Dr. Xiaolei Xu

Department of Biochemistry and
Molecular Biology, and
Department of Internal Medicine,
Division of Cardiovascular
Diseases, Mayo Clinic College of
Medicine, 200 First St. SW
Rochester, MN 55905, USA

Xu.Xiaolei@mayo.edu

Deadline for manuscript
submissions:

closed (30 June 2017)

Message from the Guest Editor

Dear Colleagues,

JCDD launches a Special Issue on “Genetics and Treatment of Dilated Cardiomyopathy”. Idiopathic dilated cardiomyopathy (DCM) is a heritable, progressive disorder that ultimately leads to heart failure. The identification of many causative genes and key pathological pathways opens the door to new therapeutic strategies. However, the development of effective therapy is significantly hindered by the heterogeneous nature of DCM, manifesting as both locus heterogeneity and phenotypic variation. Therefore, strategies that enable the categorization of DCM into different types and development of individualized medicine tailored for different DCM types are needed. The advent of genomic tools and the integration of in vitro and in vivo models offer new research opportunities to identify the remaining causative genes, to pinpoint underlying mechanisms and to identify effective therapies.

Prof. Dr. Xiaolei Xu
Guest Editor

